Adverum Biotechnologies Interest Expense 2011-2026 | ADVM

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Adverum Biotechnologies

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
8.23 M	5.75 M	-	-	-	-	4.2 M	2.7 M	762 K	370 K	18 K	73 K	8 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.23 M	8 K	2.46 M

Quarterly Interest Expense Adverum Biotechnologies

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
371 K	664 K	-	2.09 M	2.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.15 M	1.22 M	-	1.26 M	1.09 M	746 K	-	742 K	663 K	489 K	-	206 K	222 K	116 K	-	117 K	116 K	52 K	-	18 K	4 K	14 K	-	28 K	20 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.41 M	4 K	600 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
AbbVie ABBV	2.89 B	$ 232.08	3.29 %	$ 411 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.61	0.56 %	$ 1.08 B	Canada
Abeona Therapeutics ABEO	418 K	$ 5.12	-1.54 %	$ 109 M	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.66	-0.85 %	$ 773 M	Canada
ACADIA Pharmaceuticals ACAD	1.82 M	$ 24.56	-0.32 %	$ 4.07 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Achieve Life Sciences ACHV	2.85 M	$ 4.56	-3.59 %	$ 90.4 M	USA
AC Immune SA ACIU	1.89 M	$ 2.93	-1.01 %	$ 229 M	Schweiz
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aclaris Therapeutics ACRS	2.95 M	$ 2.87	-8.31 %	$ 352 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Adagene ADAG	1.11 M	$ 2.96	-4.67 %	$ 167 M	China
Adial Pharmaceuticals ADIL	-75 K	$ 2.53	-	$ 16.4 M	USA
ADMA Biologics ADMA	-212 K	$ 15.57	2.57 %	$ 3.71 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Adaptive Biotechnologies Corporation ADPT	11.8 M	$ 16.02	-2.67 %	$ 2.43 B	USA
ADiTx Therapeutics ADTX	5.84 K	$ 0.46	-4.63 %	$ 6.06 K	USA
Agenus AGEN	1.26 M	$ 3.33	-0.89 %	$ 1.19 M	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 30.23	0.83 %	$ 1.75 B	USA
AIM ImmunoTech AIM	629 K	$ 0.91	-8.59 %	$ 43.8 M	USA
Akebia Therapeutics AKBA	58 K	$ 1.31	-0.76 %	$ 337 M	USA
Akari Therapeutics, Plc AKTX	-3 K	$ 0.24	-8.87 %	$ 5.73 B	Britain
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Aldeyra Therapeutics ALDX	1.69 M	$ 5.46	-0.73 %	$ 328 M	USA
Alector ALEC	13.2 M	$ 2.43	-5.08 %	$ 250 M	USA
Aligos Therapeutics ALGS	4.3 M	$ 7.03	-6.27 %	$ 452 M	USA
Alkermes plc ALKS	4.47 M	$ 30.1	-2.05 %	$ 4.96 B	Irlanda
Allogene Therapeutics ALLO	-17.8 M	$ 2.78	1.83 %	$ 436 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Alnylam Pharmaceuticals ALNY	5.2 M	$ 332.92	0.51 %	$ 43.6 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Altimmune ALT	48 K	$ 4.31	-3.36 %	$ 306 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
ALX Oncology Holdings ALXO	1.73 M	$ 2.11	-10.21 %	$ 110 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA